Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13731002 | 0.88 | F2RL3 (0.48) | NPC1RAB9AALDH1A3F2RL3TP53 | |
| SCHEMBL13750601 | 0.81 | DYRK1A (0.41) | CSNK1DCSNK1ECYP11B2CYP11B1AHR | |
| SCHEMBL13730992 | 0.81 | RAB9A (0.50) | NPC1RAB9AALDH1A3F2RL3TP53 | |
| SCHEMBL4099914 | 0.78 | DRD2 (0.42) | CSNK1DCSNK1ECYP11B2CYP11B1AHR | |
| SCHEMBL13730155 | 0.76 | F2RL3 (0.46) | CSNK1DCSNK1EAHRNPC1RAB9A | |
| SCHEMBL798826 | 0.74 | DYRK1A (0.34) | AHRDYRK1A | |
| SCHEMBL13729698 | 0.72 | KDM4E (0.41) | NPC1RAB9ATP53MAPTDYRK1A | |
| SCHEMBL2067022 | 0.72 | DYRK1A (0.50) | AHRNPC1RAB9ADYRK1A | |
| SCHEMBL17229848 | 0.70 | AHR (0.37) | CYP11B2CYP11B1AHRALDH1A3DYRK1A | |
| SCHEMBL3342789 | 0.70 | PDE10A (0.39) | AHRDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | CSNK1D 689/4885CSNK1E 1005/4885CYP11B2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.